Skip to main content
OpenTrials

Clinical trial condition

Vaccinia

Explore clinical trials studying Vaccinia. Study availability and eligibility vary by location and protocol.

48 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Vaccinia trial results

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

NCT00001056

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • Univ. of Rochester AVEG Rochester, New York, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
View Trial Details
Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

NCT00000957

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • JHU AVEG Pittsburgh, Pennsylvania, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
View Trial Details
Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • Univ. of Rochester AVEG Rochester, New York, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details
Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +15 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details

Related conditions